scholarly journals RETROSPECTIVE ANALYSIS OF THE COURSE OF THYROID CARCINOMA WITH LUNG METASTASES AFTER RADIOIODINE THERAPY

2020 ◽  
Vol 17 (35) ◽  
pp. 728-738
Author(s):  
Olha M. ASTAPIEVA ◽  
Ganna V. GRUSHKA ◽  
Olga I. PASKEVYCH ◽  
Yuliia Ya. FEDULENKOVA ◽  
Oleksii V. MAKSIMISHYN
Keyword(s):  
Thyroid Carcinoma ◽  
Disease Progression ◽  
Radioiodine Therapy ◽  
Clinical Laboratory ◽  
Malignant Tumors ◽  
Lung Metastases ◽  
Survival Rates ◽  
Differentiated Thyroid Carcinoma ◽  
Thyroid Tumor ◽  
Medical Radiology

Metastasis of malignant tumors are one of the most acute problems of oncology. Among the organs and systems of the human body in terms of frequency of damage, one of the first places is occupied by the lungs, which is probably closely related to the anatomical features of their structure and physiology. During the first examination of cancer patients, metastases in the lungs are revealed in 6-15%, lymphogenous metastases are observed in 50-81%. With differentiated thyroid carcinoma (thyroid gland), metastases in the lung are most often detected (up to 15% of cases). At the same time, 5- and 10-year survival rates are 50-92.6% and 42-86%, respectively. The use of 131I-sodium iodide is central to the treatment of these patients. The purpose of the paper is to study the effectiveness of radioiodine therapy for metastases of thyroid carcinoma in the lung. We used clinical, laboratory, radiological methods for the diagnosis of thyroid carcinoma and pulmonary metastases. From 1986 to 2010, 68 patients from the clinic of the S.P. Hryhoriev Institute of Medical Radiology of the Academy of Medical Sciences of Ukraine were included in the study. Lung metastases were found in patients with all stages of the disease and with diverse sizes of the primary thyroid tumor. After the surgical treatment of patients, 131Isodium iodide was used in various doses of radioactivity. The full therapeutic effect of radiotherapy was achieved in 5 patients (7.8%) over a 3-year period of treatment, and a 5-year period – in 28 (43.8%); stabilization or partial effect was noted in 24 patients (37.8%), disease progression was observed in 12 patients (17.6%). Mortality from disease progression was 12.5%.

scholarly journals Does Radioiodine Therapy in Patients with Differentiated Thyroid Cancer Increase the Frequency of Another Malignant Neoplasm?

ISRN Oncology ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Renata Midori Hirosawa ◽  
Monica Marivo ◽  
Juliana de Moura Leite Luengo ◽  
Jose Vicente Tagliarini ◽  
Emanuel Cellice Castilho ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Carcinoma ◽  
Differentiated Thyroid Cancer ◽  
Radioiodine Therapy ◽  
Clinical Laboratory ◽  
Malignant Neoplasm ◽  
Differentiated Thyroid Carcinoma ◽  
Cancer Type ◽  
Primary Malignancy ◽  
The Moment

Objectives. To compare the frequency of another primary malignancy in patients with differentiated thyroid carcinoma (DTC) who received radioiodine therapy or not (131I). Material and Methods. 168 cases of DTC patients were retrospectively evaluated as to the frequency of another neoplasia by comparing patients with and without it, taking into account clinical, laboratory, and therapeutic parameters. Results. Another primary malignancy occurred in 8.9% of patients. Of these, 53.3% showed the malignancy before 131I and 46.7% after it. By comparing both groups, the age at the moment of diagnosis of another neoplasia was 46.1 ± 20.2 years for the group before 131I therapy and of 69.4 ± 11.4 years for the group after it (P=0.02). Of the 148 patients treated with 131I, 4.7% developed another malignancy. The latter were older (61 ± 17 years) than those who did not show another cancer type (44.1 ± 14.2 years) (P<0.05). Conclusion. The frequency of another neoplasia found after 131I was similar to that found before 131I.

scholarly journals Survival and Therapeutic Modalities in Patients with Bone Metastases of Differentiated Thyroid Carcinomas

2001 ◽  
Vol 86 (4) ◽  
pp. 1568-1573 ◽  
Author(s):  
Marie-Odile Bernier ◽  
Laurence Leenhardt ◽  
Catherine Hoang ◽  
Andre Aurengo ◽  
Jean-Yves Mary ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Bone Metastases ◽  
Radioiodine Therapy ◽  
Survival Rates ◽  
Young Patients ◽  
Differentiated Thyroid Carcinoma ◽  
Prognostic Features ◽  
Therapeutic Modalities ◽  
Age Range ◽  
The Impact

Data for patients with bone metastases (BMs) of differentiated thyroid carcinoma (DTC) were retrospectively studied to identify factors associated with survival. We especially studied the impact of therapies. Among the 1977 patients followed for DTC in our department from 1958 to 1999, 109 (77 females and 32 males; age range, 20–87 yr) presented BMs. All patients except 1 underwent total thyroidectomy, followed by radioiodine therapy (≥3.7 gigabecquerels) in 95 cases. Survival rates at 5 and 10 yr were 41% and 15%, respectively. Univariate analyses indicated that a young age at BM discovery (P &lt; 0.005) and the discovery of BM as a revealing symptom of DTC (P &lt; 0.05) were features significantly associated with improved survival as well as radioiodine therapy (P &lt; 10−4) and BM complete surgery (P &lt; 0.02). Using multivariate analysis, the detection of BMs as a revealing symptom of thyroid carcinoma (P &lt; 0.0005), the absence of metastasis appearance in other organs than bones during the follow-up (P &lt; 0.03), the cumulative dose of radioiodine therapy (P &lt; 0.0001), and complete BM surgery in young patients (P &lt; 0.04) appeared as independent prognostic features associated with an improved survival.

scholarly journals Synchronous intrathyroidal parathyroid carcinoma and thyroid carcinoma: case report and review of the literature

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Nadia De Falco ◽  
Giuseppe Santangelo ◽  
Fabrizio Chirico ◽  
Angelo Cangiano ◽  
Maria Giulia Sommella ◽  
...  
Keyword(s):  
Literature Review ◽  
Thyroid Carcinoma ◽  
Papillary Carcinoma ◽  
Parathyroid Carcinoma ◽  
Malignant Tumors ◽  
Gamma Probe ◽  
Differentiated Thyroid Carcinoma ◽  
Thyroid Carcinomas ◽  
First Case ◽  
Well Differentiated

Abstract Background Parathyroid carcinoma is a rare endocrine malignancy, rarer when synchronous with a non medullary well differentiated thyroid carcinoma. Parathyroid carcinoma accounts of 0.005% of all malignant tumors and it is responsible for less than 1% of primary hyperparathyroidism. The intrathyroidal localization of a parathyroid gland is not frequent with a reported prevalence of 0.2%. Carcinoma of parathyroids with intrathyroidal localization represents an even rarer finding, reported in only 16 cases described in literature. The rare constellation of synchronous parathyroid and thyroid carcinomas has prompted us to report our experience and perform literature review. Case presentation We herein report a case of a 63-years-old man with multinodular goiter and biochemical diagnosis of hyperparathyroidism. Total thyroidectomy with radio-guide technique using gamma probe after intraoperative sesta-MIBI administration and intraoperative PTH level was performed. The high radiation levels in the posterior thyroid lobe discovered an intrathyroidal parathyroid. Microscopic examination revealed a parathyroid main cell carcinoma at the posterior thyroidal left basal lobe, a classic papillary carcinoma at the same lobe and follicular variant of papillary carcinoma at the thyroidal right lobe. To the best of our knowledge, this is the first case documenting a synchronous multicentric non medullary thyroid carcinomas and intrathyroidal parathyroid carcinoma. Conclusions Our experience was reported and literature review underlining challenging difficulties in diagnostic workup and surgical management was carried out.

Sign in / Sign up

Export Citation Format

Share Document